Dodge et al., 2014 - Google Patents
Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer diseaseDodge et al., 2014
View PDF- Document ID
- 2664397185192517164
- Author
- Dodge H
- Zhu J
- Harvey D
- Saito N
- Silbert L
- Kaye J
- Koeppe R
- Albin R
- Alzheimer's Disease Neuroimaging Initiative
- et al.
- Publication year
- Publication venue
- Alzheimer's & Dementia
External Links
Snippet
Background It is unknown which commonly used Alzheimer disease (AD) biomarker values— baseline or progression—best predict longitudinal cognitive decline. Methods 526 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI). ADNI composite memory and …
- 239000000090 biomarker 0 title abstract description 135
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
- G06F19/345—Medical expert systems, neural networks or other automated diagnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
- G06F19/3437—Medical simulation or modelling, e.g. simulating the evolution of medical disorders
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dodge et al. | Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease | |
Pegueroles et al. | Longitudinal brain structural changes in preclinical Alzheimer's disease | |
Koran et al. | Sex differences in the association between AD biomarkers and cognitive decline | |
Tosto et al. | The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment | |
Da et al. | Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers | |
Vos et al. | NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers | |
Jimenez et al. | Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease | |
Bertens et al. | Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease | |
Barnes et al. | Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls | |
Toledo et al. | Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition | |
Villain et al. | Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB–PET longitudinal study | |
Wang et al. | Arterial spin labeled MRI in prodromal Alzheimer's disease: a multi-site study | |
Trzepacz et al. | Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia | |
Mak et al. | Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease | |
Brooks et al. | Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions | |
Guzman et al. | White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment | |
Han et al. | Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s disease | |
Resnick et al. | Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts | |
Schumacher et al. | Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer’s disease | |
Prestia et al. | Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series | |
Dadar et al. | The temporal relationships between white matter hyperintensities, neurodegeneration, amyloid beta, and cognition | |
Jonaitis et al. | Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease | |
Dumurgier et al. | Inverse association between CSF Aβ 42 levels and years of education in mild form of Alzheimer's disease: The cognitive reserve theory | |
Stricker et al. | CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer’s pathological cascade | |
Hohman et al. | Evaluating Alzheimer's disease biomarkers as mediators of age-related cognitive decline |